Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges (2014 - 2026)

Ani Pharmaceuticals (ANIP) has 13 years of Amortization of Deferred Charges data on file, last reported at $358000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges rose 10.49% year-over-year to $358000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 19.04% YoY), and the FY2025 full-year result was $1.8 million, up 15.27% from the prior year.
• Amortization of Deferred Charges fell to $358000.0 in Q1 2026, from $555000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $3.9 million in Q4 2023 to a low of $300000.0 in Q3 2024.
• A 5-year average of $770466.7 and a median of $555000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges surged 71.68% in 2022 and slumped 90.01% in 2024, its largest moves.
• Tracing ANIP's Amortization of Deferred Charges over 5 years: stood at $592000.0 in 2022, then jumped by 562.5% to $3.9 million in 2023, then sank by 90.01% to $392000.0 in 2024, then soared by 41.58% to $555000.0 in 2025, then tumbled by 35.5% to $358000.0 in 2026.
• Business Quant data shows ANIP's Amortization of Deferred Charges at $358000.0 in Q1 2026, $555000.0 in Q4 2025, and $500000.0 in Q3 2025.